 Connection
Yuri Zarate to Protein Kinase Inhibitors
This is a "connection" page, showing publications Yuri Zarate has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.246 |
|
|
|
-
Bouhatous YM, Bredrup C, Maurer A, Mirakovska L, Foster A, Kosaki K, Jost C, Demoulin JB, Luu M, Vabres P, Kurtz JE, Schaefer E, Guimier A, Cormier-Daire V, Lim D, Thompson S, Olson L, Kwon HR, Aguirre-Rodriguez C, Hernandez-Dorronsoro U, Martinez-Soroa I, Iznardo H, Mascar? JM, Baselga E, Kalantari S, Mussa A, Gazzin A, Carli D, Svinvik I, Mutlu-Albayrak H, Bluefeather S, Zarate Y, Takenouchi T, Naicker T, Chateau A, Gokhul A, Dube-Pule A, Haniffa M, Ong Peitee W, Nordgren A, Carpentier M, Binquet C, Briffaut AS, Bal L, Pond D, Rustad CF, Bardou M, Faivre L. 'Knowing and Treating Kosaki/Penttinen syndrome' international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors. J Med Genet. 2025 Sep 19; 62(10):656-663.
Score: 0.210
-
Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, Chenbhanich J, Heike CL, Adam MP, Chang I, Sun A, Miller DE, Beck AE, Gupta D, Boos MD, Zackai EH, Everman D, Ganapathi S, Wilson M, Christodoulou J, Zarate YA, Curry C, Li D, Guimier A, Amiel J, Hakonarson H, Webster R, Bhoj EJ, Perkins JA, Dahl JP, Dobyns WB. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020 07; 182(7):1576-1591.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|